Form 4: Processa Pharmaceuticals Officer Wendy Guy Reports Stock Transactions

Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, reports the vesting and distribution of restricted stock units and subsequent adjustments due to a reverse stock split.

Summary

• On January 1, 2024, Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, reported transactions involving common stock and restricted stock units.
• These transactions include the vesting and distribution of 1,675 restricted stock units, resulting in the acquisition of 1,675 shares of common stock.
• A portion of the shares were used to cover tax obligations, with 368 shares disposed of at a price of $2.79.
• The report also reflects adjustments due to a 20-for-1 reverse stock split that took effect on January 22, 2024.
• Following these transactions, Guy directly owns 11,433 shares and indirectly owns 8,335 shares through CorLyst, LLC.
• The report was signed by Michael B. Kirwan, as Attorney-in-Fact, on April 12, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company officer. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard disclosures required by the SEC for company insiders, providing transparency into their transactions in the company's stock. This allows investors to track insider sentiment and potential alignment with company performance.

Stakeholder Impact

• Shareholders are informed about insider transactions, which can influence their perception of the company's prospects.

Key Dates

Keywords

Form 4, Processa Pharmaceuticals, Wendy Guy, stock transactions, reverse stock split, restricted stock units, beneficial ownership